Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • avatrombopag

    - PMLiVE

    Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

    C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

    - PMLiVE

    Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

    Approximately 7,700 people in England are living with the genetic bleeding disorder

    - PMLiVE

    Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

    The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

    - PMLiVE

    Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study

    Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder

    - PMLiVE

    Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study

    There are currently no treatments that target the underlying cause of C3G or IC-MPGN

    - PMLiVE

    Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Takeda’s mezagitamab shows promise in immune thrombocytopenia

    The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually

    - PMLiVE

    Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

    The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

    - PMLiVE

    Sobi’s Aspaveli receives expanded EC approval for rare blood disorder PNH

    The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria

    - PMLiVE

    Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

    The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

    - PMLiVE

    Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia

    The late-stage LUNA 3 study results will be presented at a medical congress later this year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links